Singapore markets open in 3 hours 14 minutes

Stoke Therapeutics, Inc. (STOK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.56+0.53 (+4.81%)
At close: 04:00PM EDT
11.56 -0.00 (-0.00%)
After hours: 05:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.03
Open11.14
Bid11.53 x 100
Ask11.59 x 200
Day's range10.97 - 11.81
52-week range3.35 - 16.40
Volume788,942
Avg. volume1,268,552
Market cap602.478M
Beta (5Y monthly)0.76
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

    BEDFORD, Mass., April 29, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer. In this role, Mr. Leggett will be responsible for overseeing all aspects of the Company’s financial strategy and operations. Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his p

  • Business Wire

    Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

    BEDFORD, Mass., April 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke’s leadership te

  • Business Wire

    Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

    BEDFORD, Mass., April 04, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET.